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Abstract  
The role of fibrin in tissue repair makes fibrin microthreads ideal biological scaffolds for stem 
cells in cardiac regenerative medicine. Current cell delivery research has been proven to benefit 
ischemic heart tissue regeneration by implantation of human mesenchymal stem cells (hMSCs). 
Endothelial progenitor cells (EPCs) also help to fully regenerate tissue by encouraging 
angiogenesis. This project aims to design and fabricate a sterile seeding device that is capable of 
seeding multiple stem cell types onto different bundles of fibrin microthreads used as a surgical 
suture. The team used the provided client statement along with brainstorming methods and 
testing procedures to create a functioning design. The final design is a polydimethylsiloxane 
(PDMS) mold that contains tubing wells to hold the Silastic® tubes and threads in place. This 
design allows for gas exchange, efficient seeding of two different cell types and an ease of use 
for the user and client.  
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Chapter 1: Introduction 
The use of fibrin microthreads as a scaffold has the potential to aid in regenerating tissue in 
diseased or scarred organs. The American Heart Association estimates that in 2006, 
approximately 452,000 people had a myocardial infarction resulting in death (American Heart 
Association, 2007). Myocardial infarction (MI), or heart attack, is the number one killer of 
people in the United States resulting in a death roughly every 36 seconds. The blockage of 
oxygenated blood to the tissue will cause ischemia, and may result in cell death; this blockage 
can be caused by a buildup of plaque on the interior wall of the arteries. The death of these 
myocytes adversely affects the hearts ability to pump. Over time, the infarct region may thin. 
(Fletcher, 1981). The heart then adjusts and becomes more spherical in shape, causing it to work 
much harder than prior to the infarction. Surgery, drugs, or a combination of the two are used for 
myocardial infarction treatment. These types of treatments restore the coronary circulation, but 
these treatments do not regenerate or replace the infarct area with healthy, functional tissue. 
Stem cell therapies have been used for myocardial infarction treatment and for a number 
of other diseases.  Some future uses of stem cells include treatments for amyotrophic lateral 
sclerosis (ALS), baldness, cancer, deafness, haematopoiesis, missing teeth, spinal cord damage, 
vision impairment, and tissue engineering/drug delivery (National Institute of Health, 
2012).  Mesenchymal stem cells (MSC) are a type of adult stem cell commonly used in research 
to regenerate organ tissue. Researchers often choose to work with MSCs for their ability to 
differentiate into many cell types including adipocytes, chondrocytes, fibroblasts, myocytes, 
osteocytes, stroma, and tenoblasts (Pittenger, 1999). 
The goal of this project was to develop a process to seed two or more cell lines onto two 
different fibrin microthread bundles attached to the same suture needle. The design must be safe 
for the patient and the user. The suture must be able to be sterilized and implanted during 
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surgeries. Currently, a fibrin thread bundle can be seeded with only one cell type. This new 
design allows the user to include one or more cell lines onto different ratios of threads in a 
suture. 
Chapter 2: Literature Review 
Heart Disease 
Cardiovascular disease, or heart disease, is the leading cause of death in both men and women in 
the United States and worldwide; the incident continues to increase every year (CDC, 2012). The 
causes of cardiovascular disease include obesity, diabetes, high blood pressure, smoking, lack of 
exercise, and a family history of the disease (Thomson Healthcare, Inc., 2011). Unfortunately, as 
obesity levels continue to rise in the US, there may be a concomitant increase in the occurrence 
of heart disease. The term “cardiovascular disease” includes a range of illnesses such as 
myocardial infarction, angina, arrhythmias, and congenital heart defects (Mayo Clinic, 2012). 
Coronary heart disease is the narrowing of the blood vessels which supply the heart with blood 
and oxygen, ultimately leading to angina or myocardial infarction through the lack of oxygen 
(PubMed Health, 2011). 
Myocardial infarction, more commonly known as heart attack, occurs as the result of 
heart tissue being deprived of oxygen and eventually dying (Thomson Healthcare, Inc., 2011). 
The most common cause of the oxygen deprivation is narrowing of the coronary arteries, often 
by plaque (Thomson Healthcare, Inc., 2011). This can result in chest pain known as angina, 
which can limit a person’s activity, but does not result in permanent damage to the myocardium. 
The tissue can also suffer when a blood clot forms on or around these fatty deposits of plaque, 
obstructing the coronary artery and leading to a myocardial infarction with permanent loss of 
myocardium. 
Myocardial infarction can occur as a result of coronary artery spasm, heart valve 
problems, and sudden severe stress (Thomson Healthcare, Inc., 2011). Though these causes are 
not as common, they can often be just as life-threatening as plaque buildup. 
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Current Myocardial Infarction Treatments 
Common infarction treatments involve angioplasty, surgery, drugs, or a combination of the 
preceding. Many different types of drugs are used to treat myocardial infarctions including 
thrombolytic, antiplatelet agents, antiarrhythmic, beta-blockers, calcium channel blockers, 
statins, and Angiotensin converting enzyme (ACE) inhibitors. Aspirin is often prescribed at the 
time of an infarction to inhibit platelet functions and after the attack to decrease the chance of 
recurrence. Each drug plays a role in the treatment and recovery of the patient. To dissolve blood 
clots, physicians prescribe thrombolytic therapies; whereas, antiarrhythmic therapies are used to 
control abnormal rhythms. Often after an infarction, a patient’s heart can beat faster than it did 
prior to the attack; beta-blockers are used to slow the patient’s heart rate and lower blood 
pressure, in turn preventing irregular heartbeats. This will reduce the work of the heart and lower 
the heart’s requirement for blood and oxygen. Calcium channels are known to directly affect a 
patient’s blood pressure. Calcium channel blockers lower blood pressure and also relieve chest 
pain. ACE inhibitors act similarly to calcium channel blockers in that they lower blood pressure; 
in addition, they affect cardiac remodeling after an infarction. Since blood vessels tend to narrow 
after an attack, statins have been used to prevent blood vessel narrowing and to lower blood 
cholesterol (Hwang, M.E.Y., 1999). 
Drugs used to treat infarctions must be administered to the patient within twelve hours of 
occurrence. These drugs are delivered intravenously and travel to the clot or occlusion to 
dissolve it and allow blood flow back to the heart. These drugs work best when administered 
within the first hour after the patient has had the myocardial infarction (Herlitz, 1989). Some 
common drugs given to patients after the initial treatment to break up the clot are aspirin, 
superaspirin, pain relievers, nitroglycerin, beta blockers, cholesterol lowering medication, and 
anticoagulants like warfarin (Mayo Clinic, 2012). 
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Typical surgical procedures like stenting, percutaneous transluminal coronary angioplasty 
(P.T.C.A.) and coronary artery bypass grafts (C.A.B.G.) are used to repair or bypass the 
occlusion. These surgeries do not attempt to restore living cells or mechanical function to the 
infarcted region of the heart. In C.A.B.G., the cardiovascular surgeon opens the thoracic cavity to 
reveal the heart. The surgeon then attaches an autologous blood vessel to the heart, 
circumventing the occlusion to allow blood flow to the regions beyond the blockage. 
Angioplasty is the procedure in which the cardiologist uses an inflated balloon inside the vessel 
to widen the coronary artery (Hwang, M.E.Y., 1999). 
 
Scaffolds 
There are several current stem cell delivery methods including intravenous (IV) delivery, 
intracoronary (IC), and endocardial (EC) (Freymen, 2006). Intravenous delivery occurs by 
delivering the cells through the patient’s blood stream; during intracoronary delivery, cells are 
commonly delivered through a catheter in the heart to a specific area and during endocardial 
delivery, cells are delivered directly through injection into the heart tissue (Freymen, 2006, 
Brown, 2004). Endocardial delivery has not been shown to have a connection to decreased 
coronary blood flow like intracoronary delivery has, yet IC has one of the higher rates of 
efficient cell delivery (Freymen, 2006). Another way to deliver cells to the heart is through the 
use of a scaffold. 
A scaffold is a material that is used to provide structure and to also serve as an 
attachment site for cells. They are used to transport and deliver cells to a specific location. In 
order to ensure ideal nutrition, the diffusion barrier of the scaffold must be as low as possible. 
Scaffolds are currently made of synthetic polymers, natural polymers or biological materials 
(Jockenhoevel, 2001). Some synthetic polymers include polyurethanes and polylactic acid 
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(Jockenhoevel, 2001) can be used for soft tissue applications (Guan, 2004) and cartilage repair, 
(Chu, 2004) respectively. Natural polymers include glycosaminoglycan and collagen 
(Jockenhoevel, 2001), which can be combined to assist with bone and cartilage growth (O’Brien, 
2006), or collagen can be used on its own for tissue engineering. An example of a biological 
scaffold is acellularized porcine aortic conduit (Jockenhoevel, 2001), which is used as a heart 
valve scaffold (Leyh, 2003). Natural polymers have a decreased risk of negative patient reaction, 
especially if the scaffold is an autologous polymer (Jockenhoevel, 2001). For this reason, 
collagen and fibrin are two widely used polymers.  
 
Fibrin 
When used as a scaffold, fibrin not only provides support and easy degradation to its host, but it 
also assists with cell orientation when used as a microthread (Cornwell, 2007). Research by 
Cornwell and Pins shows that using microthreads instead of gels as a scaffold not only increases 
the mechanical strength of the scaffold, but it also provides the support needed for successful cell 
engraftment (Cornwell, 2007). Fibrin is a protein located in the provisional matrix of animal 
cells. Its main functions are to provide support for the cell and to assist in the healing process. 
When a wound is formed, fibrin is created to stop the flow of blood so that the body can begin to 
repair (Cornwell, 2007, Proulx, 2010 and Clark, 2003). The fibrin clots with the platelets, 
creating a provisional matrix that not only maintains effective hemostasis but also guides the 
other cells involved in the healing process to their points of attachment for proper wound healing 
(Clark, 2003). Fibrin is formed when fibrinogen and thrombin congregate. Fibrinogen is a 
hexameric glycoprotein that is produced in the liver by pairs of three gene products. Fibrinogen 
is present in the blood at a level of about 3 mg/ml (Clark, 2003). Thrombin is the enzyme that 
changes fibrinogen into fibrin, this occurs at the end of the blood coagulation process (Clark, 
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2003). The fibrin matrix is not only able to support cell growth, but it also assists in cell 
attachment and direction once the fibrin clot is fully incorporated in the wound tissue. Once 
incorporated, the clot becomes housing for proteases as well as for protease inhibitors, which 
regulate further coagulation and breaking down of the clot, respectively (Clark, 2003). 
There are many benefits to creating scaffolds using fibrin; for example, it is currently 
Food and Drug Administration (FDA) approved, the fibrinogen and thrombin can be harvested 
from the patient, which lowers the chance of rejection, it assists in wound healing and it 
promotes cell recruitment, growth and attachment (Proulx, 2010).  
Fibrin can either be used as a gel scaffold or as a microthread scaffold. As a gel, fibrin 
can be easily transported and it is biodegradable, but fibrin gel also has a low mechanical 
stiffness initially so there is a chance of shrinking (Jockenhoevel, 2001). Microthreads on the 
other hand, are not only biodegradable but they also present all of the biological properties of 
fibrin, while adding more strength than the gels. This allows for the threads to deliver the cells to 
the targeted area as well as to provide support and structure for the cells (Proulx, 2010, Clark, 
2003). 
 
Stem Cells 
Stem cells are cells that have the ability to differentiate into many different cell lineages. These 
cells are able to repair and replace injured or infected tissues by relatively unrestricted cell 
division in living organisms. Stem cells have been known to remain undifferentiated. They also 
have the ability to differentiate most commonly into myoblasts, osteoblasts, and neuroblasts. 
These divisions allow the cells to further specialize into connective and structural tissues. Stem 
cells can be grouped into two main groups, embryonic and adult stem cells. Embryonic stem 
cells are harvested from the blastocyst stage of development. These cells are totipotent, which 
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allows them to differentiate into any tissue. Adult stem cells are found in specific organs and can 
only differentiate into the tissue of that organ. 
 
Mesenchymal Stem Cells 
In stem cell research, human mesenchymal stem cells (hMSCs) have been used for organ 
regeneration including heart muscle tissue; they are self-regenerating and pluripotent. These cells 
have the ability to divide creating multiple similar cells. They can also differentiate into many 
different cellular lineages, including adipocytes, chondrocytes, fibroblasts, myocytes, osteocytes, 
stroma, and tenoblasts (Pittenger, 1999). Bone marrow is a common site for harvesting these 
cells. Other places for harvesting cells include stroma, spleen, umbilical cord, thymus and 
synovial fluid. According to past studies, MSCs have a relatively low response rate and clearance 
by the immune system (Pittenger, 1999 and Pountos, 2005). This limited antigenicity is one 
reason why many researchers choose to engraft these cells over other cell lineages.  
Culturing hMSCs 
Dr. Friedenstein in the late 1970s developed a method to isolate and culture MSCs, which was 
updated in the 1990s (Pittenger, 1999). This method has become one of the most common 
practices for harvesting MSCs. Bone marrow is a common site for harvesting these cells. Bone 
marrow derived mononuclear cells (MNCs) are isolated and prepped using density 
sedimentation. After culturing for 48 hours, the non-adherent hematopoietic cells are separated 
from the MNCs. The homogeneous MSCs adhere to the container. Alkaline phosphates (ALP) 
have been used to identify MSCs. If the cells are positive they are identified as MSCs since 
ALP+ reticular cells are similar to MSCs (Deans, 2000). 
Mesenchymal stem cells have been used to repair heart muscle in rats and other animals. 
Since MSCs are pluripotent, the cells have the ability to differentiate into an unintended cell 
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lineage. To prevent this, specific medium and growth factors can be introduced to the cell during 
cell culture to keep the cells in their pluripotent form before being sutured into the heart. From 
the research conducted, simple injection can lead to a low engraftment number. The use of a 
scaffold has been able to increase the number of cells engrafted by upwards of 60% 
(Fakharzadeh, 2010). 
 
Endothelial Progenitor Cells 
Endothelial progenitor cells (EPCs) are a subtype of progenitor cells derived from bone marrow 
that are capable of differentiating into mature endothelial cells (Hristov, 2003). Progenitor cells 
are similar to stem cells in their ability to differentiate into a specific type of cell, but are 
different due to their specificity. EPCs have been shown to augment neovascularization, or the 
growth of blood vessels, of ischemic tissue in major organs after a trauma (Hristov, 2003 and 
Urbich, 2004). Progenitor cells have been used as opposed to mature endothelial cells because 
there is supporting evidence suggesting that EPCs take part in angiogenesis, whereas mature 
cells have limited regenerative capabilities (Shantsila, 2006). The greatest limitation currently is 
the lack of understanding the signals needed to attract EPCs to the injury site. Patients have 
EPCs circulating in the peripheral blood and residing in the spleen as well as the bone marrow. 
EPCs have been exposed to the injury site through surgical injections rather than 
intravenously since most of the cells get pumped out of the heart this way (Shantsila, 2006). In 
ischemic mouse tissue, EPCs have shown to improve blood flow and reduce scarring as well as 
to encourage overall heart function improvement (Urbich, 2004). 
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PDMS 
Polydimethylsiloxane (PDMS) is an organic silicon compound that is simple to make and can be 
used for a variety of laboratory applications (Albright Technologies Inc., 2011). Some of these 
applications include implants, valves, orthopedics, catheters, etc. (Albright Technologies Inc., 
2011). The process of creating PDMS is as simple as mixing two agents, placing the mixture in a 
vacuum for an hour, and allowing the mixture to set in an oven overnight. For this reason, and 
also because PDMS is inflammable as well as non-toxic, it is highly desired and used by many. 
However, the most significant feature of PDMS may be its outstanding flexibility (Dow Corning, 
2012). The chemical makeup of PDMS consists of long bonds with low rotation barriers and a 
wide bond angle, as seen in the Figure 1, below (Dow Corning, 2012). These characteristics give 
PDMS its unique flexibility, clarity and widespread application to biomedical experiments.  
Polar inorganic backbone  
 Long and strong Si-O 
bond; open Si-O-Si 
angle  
 
 Low barrier to rotation  
 Low rotation energy  
 
Nonpolar organic 
substituents (methyl)  
 Shorter Si-C bond  
 No steric hindrance to 
the methyl group  
 Ease of reorientation  
 Weak intermolecular 
forces  
 Opportunity to 
substitute other 
functional groups  
Figure 1: PDMS characteristics and composition (Dow Corning, 2012) 
Chapter 3: Project Strategy 
This project was completed between the months of April 2012 and June 2012. The project 
focused on creating one microthread bundle with two different cell types, which posed many 
problems from the existing model. Dr. Gaudette and Mark Kowaleski were assets throughout the 
entire project and played the roles of both user and advisor. 
Initial Client Statement 
The initial client statement was as follows: Facilitate the process of cell seeding and devise a way 
to seed two different stem cell types in a controllable manner for one injection. 
Objectives 
The group created a list of objectives, which the design had to meet in order to be successful. 
The design must most importantly be safe for all members involved: the user, the patient, and the 
cells. Next, the design must be versatile so that it can be moved from the laboratory to the 
operating room easily. It must also have the ability to accompany a wide range of threads in one 
bundle, at a range of lengths, and it must be able to accompany different needle sizes. Finally, 
the design should have efficient cell seeding; otherwise, it would be just as easy to continue 
using current designs if the seeding is not greater or easier than current methods. 
Constraints 
The most pressing constraint on this project is time: the group had a deadline of June 28th and a 
budget of $468 with which to work. For the design to work it must be sterile and safe for those 
involved with a seeding at or greater than current methods. 
 
Clarification of Initial Client Statement 
The initial client statement left many questions unanswered, but it also allowed the group great 
range in deciding how to best solve the problem at hand. A considerable amount of research was 
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conducted about the two specific cell types intended for this project, among other important 
topics. Discussions were held with other students in lab and in the BME department to get ideas 
as to which parts of the process could be improved. The group observed a detailed run-through 
of the entire thread process, which was crucial to understanding how the process is currently 
undergone and where the group can hope to amend it. After these discussions, we came up with a 
revised client statement which reads as follows: Our design seeks to seed two cell types onto a 
fibrin microthread bundle, of desired length, connected to a sterile needle in a way that is both 
safe and cost-effective for the user and client. This will be completed by June 28th under a 
budget of $468. 
Project Approach 
Specific Aims 
Our project aims to allow the control of cell solution on a specific microthread bundle; thus 
ensuring the solutions are not mixed. Another important aim is to maximize cell 
attachment/seeding. Therefore, after completing a run-through of the cell seeding process, our 
group will count the number of live cells on the suture and estimate a percentage of live cell 
attachment. 
Chapter 4: Designs 
This section discusses our client statement and uses our objectives, functions, constraints and 
specifications to create preliminary designs that lead to our final design. 
Initial Client Statement 
To create the initial client statement we met with Dr. Gaudette and discussed his expectations for 
our project. The group found that the main goals of the project could be stated as such: 
Facilitate the process of cell seeding and devise a way to seed two different stem cell types in a 
controllable manner for one injection. 
We then conducted research and looked further into the objectives, functions, constraints and 
specifications to revise our client statement. 
Needs Analysis 
Objectives 
The group began by identifying the main objectives: safety, separation of cells, construction, 
versatility and efficient seeding. 
Safety 
Within safety the group needed to watch for the safety of the user, the patient and the cell. 
Factors included in safety are low possibility of thread failure, needle failure and non-toxic 
solution for the cell. Factors included in cell safety are the guarantee that the device is non-toxic 
to the cell and the maintenance of cell viability. For the cells to be viable, the device must allow 
for good oxygen flow, maintain the right temperature and withstand temperatures used in the 
seeding process. 
Separate Cells 
In order to achieve the objective of keeping the cells separate, they must be kept apart for loading 
and incubation. During incubation, the cells must stay separate both before and after bundling. 
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Construction 
For efficient construction, the microthreads need to be properly bundled. The device must also 
properly contain all parts through tubing and clamping, while the needle must have a strong hold 
and not create a large user interface.  The cost of materials used in our design along with the cost 
of labor need to be relatively low for the user/client. 
Versatility 
Versatility of our design is also an important objective. It should allow for a varying amount of 
threads to be loaded with modified lengths (it should be able to be used in rats for testing as well 
as in humans). The device must accommodate different needle sizes and it should be easy to use, 
durable, portable, shippable, and scalable. 
Efficient Seeding 
It is also important that the cells in our device are efficiently seeded. There needs to be a high 
percentage of cells incubated while maximizing the number of cells loaded and minimizing cell 
death. 
Constraints 
The group design has to be safe and non-hazardous; it also has to be able to be sterilized. We are 
restricted to a budget of $468 and a time frame of 7 weeks. 
We created pairwise comparison charts (PCC) to evaluate the order of importance of the 
objectives. Dr. Gaudette, Mark Kowaleski, and the members of the MQP team each filled out 
their own chart. A blank chart is shown below. 
 
 
24 
 
 
Figure 2: Blank PCC 
Also, a morphological chart was made to determine the ways to achieve the necessary functions 
for our design. (See Appendix D for Morphological Chart) 
Functions (Specifications) 
Functions 
Our design is meant to contain a needle with two bundles attached. These bundles will then be 
used to seed two different types of cells. One end of our design will be clamped. The device 
needs to hold the threads, cells and solutions and it needs to be completed in a sterile 
environment. 
Specifications 
Our design must be able to hold a needle, which is attached to between 4 and 20 threads 
somewhere within the lengths of 2-10 cm. It must also have a seeding efficiency of greater than 
or equal to 5 percent. 
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Revised Client Statement 
Our design seeks to seed two cell types onto a fibrin microthread bundle, of desired length, 
connected to a sterile needle in a way that is both safe and cost-effective for the user and client. 
This will be completed by June 28th under a budget of $468.  
Feasibility Study 
During our initial brainstorming process we came up with several designs in which we modified 
the currently used needle to accommodate two sutures. Three designs were developed. They 
were the double eye magnetic needle design, the clip in needle design and the drill end suture 
needle design.  Several other types of needles were analyzed for possible applications to the 
project. After spending time analyzing these needles, it was realized that manufacturing a new 
type of needle would not fit into the scope of our project and we began looking for a new 
solution. 
Conceptual Designs 
Double eyed magnetic needle 
In this design, the needle would be made out of steel and there would be a magnet on the inside 
of the split part of the needle. It would be a 1cm 3/8-circle, tapered needle that splits at the end. 
The ends of the needle would contain opposing magnets that would draw the needle together at 
the time of surgery. The two different microthread bundles would be threaded on each of the 
eyes of the needle and then inserted into plastic tubing to then be seeded. When the surgeon is 
ready to use the threads, he/she would pull the needle out of the tubing and the magnetic ends 
will attract to each other. The needle can then be pulled through the heart. (See Appendix B) 
Unfortunately, due to time and budget we were not able to look into creating this needle. 
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Drill end suture needle 
This design consists of a steel needle with a hollow end instead of an eye. The dried bundles 
would be inserted into the hollow end and use a tool to clamp the needle onto the threads. The 
bundles would be encased in a tube and seeded. Once needed for surgery, the suture would be 
taken out of the tubes and inserted into the heart. (See Appendix B) 
The appliances needed for this needle were too expensive so the group was unable to 
follow through with this design.  
Clip-in Needle Design 
The needle used for the sutures will have a clip-in auxiliary thread attached to the drill end side 
of the needle. The needle will have a drill end and an eye. The drill end will be crimped or 
crushed around the fibrin thread bundle of 12 or less threads. The eye will be used as an 
attachment point for the pressure fit plastic disk half needle to secure to the suturable needle. The 
half needle will be similar to the suture needle with the exclusion of the sharp point of the suture 
needle and the inclusion of a horizontal plastic disk to pressure fit into the eye of the suturable 
needle. Each thread bundle would be encased in Silastic® tubing with clips to ensure sterile 
seeding. The manufacturing of this needle was outside the scope of our project and therefore, the 
group did not follow through with this design. (See Appendix B) 
Alternative Designs 
For CAD designs of each mold, see Appendix C. 
PDMS mold 1 
The first PDMS mold design was a design that did not require clamps. In this design method, the 
PDMS would have two lines that the tubing containing the threads would perfectly fit into. These 
two lines would lead to an open rectangle, or “media bath”, where the threads would meet at the 
needle head and the needle would be pushed into the PDMS to hold it in place until surgery. The 
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two different cells would be seeded in each tube and there would be plain media in the media 
bath to keep the threads in this part hydrated and also to keep the two cell types separated. 
PDMS mold 2 
The second PDMS mold design used three round discs of PDMS. The first two had holes 
equidistant from each other along the perimeter of the discs, sized to fit the tubing and holes in 
the middle that attached the discs to the conical tube rotator. The last disc had only a hole in the 
middle to fit around the conical tube rotator. In this design the tubing was put through the 
PDMS, the threads were placed into the tubes where the injection needles would be. Then the 
tubing, the injection needles and threads were clamped in place. The needle attached to both of 
the sutures was pressed into the top disc to keep it in place and then the cells were seeded 
through the injection needles in the tubing. After seeding, the other end of the tubes were 
clamped and the whole design was put in the incubator and left to rotate overnight. 
PDMS mold 3 
The third PDMS mold was a rectangle with four long triangular wells, and a hole in the center of 
the mold, hovering over the wells. The threads would be laid in the wells without tubing and then 
the solution would be added on top. There would be a cover that allowed for oxygen diffusion 
and the design would either stay static or be placed on a conical tube rotator and be rotated while 
in the incubator. Unfortunately, the group was unable to follow through with this design because 
the slide-in piece, which fit into the center hold of the mold, did not remove easily and the 
PDMS was then compromised. 
Final Design 
At this point, the group looked back to the original designs to see what could be done next. 
Revisions were then made to the first PDMS design. The “media bath” was removed and the 
tubing support was angled in order to decrease the amount of unseeded thread. Also for this 
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design, the group cut out the PDMS about 6 mm along where the tubing lay in order to allow for 
proper gas exchange. The group made sure that the tubing extended past the end of the PDMS so 
that the solutions could be loaded through the extended tubing and the design could be clamped 
before being placed in the incubator to allow for cell attachment.  
Preliminary Data 
Two preliminary tests were performed. First, the suture-loading test was performed. In this test 
the suture was loaded into our design to make sure that it was successfully held. PDMS 1 was 
not able to hold the suture, PDMS 2 and the final design both passed this test. The second test 
was the media retention test in which the designs were loaded with threads and media, followed 
by 24 hour incubation. PDMS 2 and the final design were able to retain the media for the full 24 
hours.  
 
Chapter 5: Methodology 
In this chapter, the methods, protocols, and analysis of the experiment materials and tests are 
discussed. This chapter explains the process of production of fibrin microthreads, the stem cell 
seeding protocol, and the methods for analysis.   
Cell Culture 
Passage 7 hMSCs supplied by Mark Kowaleski were thawed to serve as experimental cells. The 
group cultured the cells from the first week of the project up until the last week. The thawing 
protocol can be found in Appendix A. Dulbecco’s modified Eagle’s Medium (DMEM; 
Mediatech, Herndon, VA) was used to culture the cells. The DMEM was enhanced by the 
addition of 1% Penicillin-Streptomyocin (Pen/Strep; Mediatech, Herndon, VA) and 10% fetal 
bovine serum (FBS; Mediatech, Herndon, VA). To maintain the sterility of the cells, all aspects 
of cell culture were completed in a biological safety hood. The cells were kept in an incubator at 
37°C at 5% CO2 in T-75 tissue culture treated flasks. Cell culture media was changed every 
week on Monday, Wednesday, and Friday. When one of the cultures was around 80% confluent, 
the cells were passaged. Cell culture protocol can be found in Appendix A. 
Passaging Cells 
When the cells became 80-100% confluent, the group passaged them into two separate flasks in 
order to ensure adequate growth. Trypsin (VWR, Philadelphia, PA) was used to detach the cells 
from the base of the container. The cells were centrifuged and counted on a hemocytometer. 
Trypan blue was used to stain and identify dead cells.  Cell passage protocol can be found in 
Appendix A. 
Fibrin Microthread Production 
Fibrin microthreads were created using the laboratory thread machine. (See Appendix A for 
Protocol) Aliquots were obtained of both thrombin and fibrinogen. The group started preparation 
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for the machine by obtaining a certain amount of thrombin and fibrinogen into two separate 
syringes, then loading the syringes into the machine. After preparing the syringes the machine 
was started. The machine created thread lines in a bath of HEPES buffered saline solution. After 
each pass of fibrin drawn by the machine, the group monitored the bath for clots. Once the 
threads were created the entire bath was removed and the threads consolidated further. After 
roughly 5 minutes, the threads were removed and stretched using the pull of the bath solution to 
gently pull each thread to approximately double its original length. Each thread was laid across 
the drying rack and left overnight to dry. Once dried, each thread was removed from the rack and 
stored in aluminum foil in the desiccator to prevent the open air humidity from deteriorating the 
threads. 
Thread Bundling 
The group chose to use bundles of six threads for the project in order to obtain one final bundle 
of 12 threads. To create these bundles, six microthreads were laid parallel to one another. Each 
thread was attached to a single piece of tape. The designated “top ends” of the threads were 
attached as closely together as possible and the tape was folded over so that the adhesive was 
fully covered. The part of the threads covered by tape was then clipped to the thread hanger 
(Figure 3) and hydrated with deionized (DI) water, then twisted and gently stretched. The bundle 
was then clamped on the other end and left to dry for 10-15min.  
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Figure 3: Thread Hanger with bundle being stretched 
Quantum Dot 
Since the group used one cell line instead of two different cell lines, a fluorescent tag of one cell 
culture was used to differentiate between the two thread bundles created. Quantum dots were 
chosen as the tag to be added to one cell culture and used to represent the second cell type. A 
mixture of 10ml media and 10µl Qdot solution was made then media of one culture was replaced 
by this new mixture. The culture was placed back into the incubator; after 24 hours, the Qdot 
media mixture was replaced by media and imaged. (For Protocol, see Appendix A) 
Fixing Cells/Hoechst Staining 
Before seeding the cells, 100 µl of cells in media from each cell culture container was pipetted 
into one wells of a 24 well plate. These cells were Hoechst stained and imaged for cell viability.  
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To Hoechst stain, the bundles were cut from the needle and laid on microscopy slides. 
Phosphorous buffered saline (PBS) was used to wash the threads of any debris for 5 minutes 3 
times before and after covering the bundles with Hoechst stain in the PBS solution. After 
washing with PBS, the threads were placed in a slide staining box and covered with Hoechst 
stain and PBS. For each subsequent PBS wash, the threads were covered to prevent the Hoechst 
stain from losing emission signal. (See Appendix A for Hoechst staining protocol) 
Loading two bundles on one needle 
To load the bundles onto the needle, the group cut one bundle into 8cm pieces, generally yielding 
two pieces per bundle. One 8cm piece was put through the eye of the needle and hydrated. Once 
the thread was hydrated, the piece was folded over evenly and twisted together, then laid flat to 
dry. After the bundle had dried, the next bundle was pulled through the eye of the needle and 
water was dropped onto the bundle to hydrate it. Each subsequent bundle was prepared in the 
same manner, with two per needle. Once dry, the needle and the two bundles were prepared for 
cell loading. 
Making Molds 
The group recognized the need for a PDMS template of a certain design. In order to create that 
template, the group began by forming SolidWorks designs on the computer. SolidWorks is a 3-
dimensional CAD computer software program that accurately measures dimensions and allows 
for sculpting of 3D images. The CAD drawings were then sent to the Mechanical Engineering 
department at WPI in order to be rapid prototyped and created into plastic molds. These 
Acrylonitrile Butadiene Styrene (ABS) plastic molds were then filled with PDMS to create the 
templates. 
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Making Polydimethylsiloxane (PDMS) 
To make the PDMS, the group combined one part Sylgard® Elastomer Curing Agent to ten parts 
Sylgard® Elastomer Base and mixed them well in a weigh boat. Once thoroughly mixed, the 
solution was then poured into the prototyped mold and placed into a vacuum chamber. The 
PDMS mixture was left in the vacuum chamber for up to 2 hours, or until all of the air bubbles 
were removed. A vacuum attachment was used to force the bubbles out of the PDMS solution. 
The mold was placed into a 60°C oven overnight and the PDMS was removed from the mold on 
the following day. 
PDMS 1 Testing 
Once the mold was created, the PDMS was cut to the desired size. The tubes were placed in 
position. The sutures attempted to be placed into the design were not successful. (Figure 4) 
 
Figure 4: Parallel Tubing Mold 
PDMS 2 Testing 
Once all of the pieces to our design were assembled, the design was placed on the conical tube 
rotating machine. The tubing was inserted into the designated tubing holes. The injection needle 
was placed through the PDMS into the Silastic® tubing to inject the media. This was done to 
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each suture. Media was inserted through the injection needles and the design was clamped at the 
opposite end. A media retention test was performed to determine if the design could retain the 
fluids and prevent media loss. The design was placed on the conical tube rotator and left in the 
incubator overnight. (Figure 5) 
 
Figure 5: Rotating Disc Design 
PDMS 3 Testing 
The third PDMS mold was created and cut to sandwich the Silastic® tubing with the fibrin 
threads between the two molds. The excess part of the mold was cut to allow for the tubing to be 
clamped. The tubing and sutures were then set in place and the binder clips clamped the two 
halves together so that there was no space between the PDMS halves. Once done, the media was 
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added to the tubes through the extruding end, then these ends were clamped and the design was 
loaded onto the rotating machine and placed into the incubator. (Figure 6)  
 
 
Figure 6: V-Design PDMS
Chapter 6: Design Verification  
After receiving the Acrylonitrile Butadiene Styrene (ABS) plastic rapid prototypes from the 
Mechanical Engineering Department, the group developed a series of tests to determine whether 
the design met the criteria established in the objectives.  
Media Retention Test 
Before loading the bundles with cells, the group elected to perform media retention tests on each 
design that had been successful to that point. The media, without cells, was loaded into a syringe 
and injected into the tubing, then clamped at the injection end. Each tube was injected with 100 
µl, the same amount of media loaded when cell seeding. The side opposite the injection was 
sealed by clamps over the two PDMS pieces.  For the PDMS mold 2, there was no media loss 
after 24 hours of incubation. (Figure 7) The final design was also tested and it retained all 200 µl 
media for the entire 24 hours; therefore, the group proceeded with the cell seeding test. 
 
Figure 7: Conical Tube Rotator 
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Cell Seeding Test  
The final test was used to determine if the cells would adhere to the threads on the suture. 
Human mesenchymal stem cells were cultured in separate containers; one container contained 
about 110,000 quantum dot loaded cells while the other contained about 290,000 non-quantum 
dot loaded cells. The quantum dot loaded cells represented the second type of cell used in 
seeding. The quantum dots allowed the group to distinguish the threads in analysis. The PDMS 
mold 2 was being prepped for seeding trials when one of the threads broke due to dehydration. 
The final design was seeded for 24 hours; however, there was an opening in the quantum dot 
loaded hMSC tube. This opening was caused by the needle position with the PDMS and the 
failure to have the clamp close enough to the tube opening. The Qdot cells in media leaked from 
the opening. The threads became dehydrated and shorter in length. One milliliter of media with 
cells was pipetted into one well of a 24 well plate for each of the solutions. These wells were 
fixed and imaged to show the cell viability and uptake of quantum dot solution prior to loading.  
An estimated 142 cells were seen in the image of the quantum dot loaded hMSC bundle. 
Approximately 3,721 cells were believed to be in the live non-quantum dot loaded tube. 
Image Analysis 
After seeding, the suture was extracted from the final design mold and laid on microscopy slides. 
The thread bundles were cut from the suture needle and stained with Hoechst stain to determine 
the viability of the cells attached. (For Hoechst staining protocol, see Appendix A). The threads 
were imaged under a fluorescent microscope and these images were analyzed using ImageJ® 
software. The fluorescent stained cells were counted in each image and the number of cells on 
the suture was estimated.  
Chapter 7: Discussion 
This section serves to interpret the results of the final design cell seeding efficiency testing. 
Final Design 
Since the final design passed the media retention test, the device was then testing on cell seeding 
efficiency. 
The final design passed the media retention test- it effectively contained the full 200 µl 
overnight in the incubator without leaking. Therefore, the device was tested with cells: hMSCs to 
seed one bundle and the Qdot hMSCs to seed the other. (Figure 8) Each tube was injected with 
cells in media, at the quantity of 100 µl; the device was then placed in the incubator to allow 
proper seeding for 24 hours. The device was removed from the incubator on the following day 
and it was found that one of the tubes had unfortunately leaked, which meant that a great deal of 
the cells were likely lost. However, the threads were imaged the cells were counted so that the 
data could be summarized. (See Figures 9 and 10 below for the cell images) Images of the cells 
on suture can be found in Appendix B. The cells in one image were counted and scientific 
estimation was used to come up with a total number of cells on each bundle.  
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Figure 8: Quantum dot loaded cells 
 
Figure 9: Quantum dot loaded cells on bundle 
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Figure 10: Non-quantum dot loaded cells on bundle 
There were approximately 142 Qdot loaded cells on one bundle, while the other bundle 
had about 3,721 non Qdot loaded cells. An estimated 27,000 Qdot loaded cells were injected; 
therefore, the seeding efficiency for the Qdot solution was less than 1%. For the non Qdot loaded 
cell, an estimated 70,000 cells were injected which resulted in a seeding efficiency of 5%. The 
minimum efficiency of 5% cell seeding was met with this trial and time constraints did not allow 
for a second trial to improve upon the seeding efficiency. The reasoning behind the lack of Qdot 
loaded cells on the suture revolves around the media leak overnight. It is possible that once the 
device was placed in the incubator, the media seeped out of the PDMS and the cells were lost in 
the incubator; however, it is also possible that the cells had proper time to attach to the bundle 
but the media leaked out sometime before the device was removed in the morning and the cells 
died. In either scenario, many cells were lost and the minimum seeding efficiency was not met 
for the Qdot bundle. 
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This design did not size up to the current methods for seeding one cell type since the 
average seeding efficiency is usually upwards of 12%. However, the final design is a great 
starting point for future research into two-cell seeding methods in a contained environment. 
Objectives Met 
The device met the most important objectives and constraints and far exceeded any initial 
expectations for a final product. The cells were kept healthy and safe in a non-toxic environment 
which allowed gas exchange through the permeable Silastic® tubing. The device did not pose 
any safety issues for the user more than the current method poses. The cells were kept 
completely separate during both loading and incubation; they were only exposed to one another 
when the suture was pulled out of the device and a final bundle was formed. The fibrin 
microthread bundles were created based on current methods and the bundles were placed through 
the eye of the needle quite easily. Since the needle and microthreads used were not different 
from those of the current seeding process, the strength of the suture is maintained. 
The materials used and the time needed to use the device are the same as current 
methods; therefore, the cost to the user and client is still inexpensive. The device, although not 
perfect, is aesthetically pleasing and easy to use. Since the PDMS mold can be made to be any 
size needed, the bundles have the ability to be any length and may be comprised to however 
many threads required for efficient seeding. This is assuming that the length will not be too large, 
i.e. 20cm and the thread bundle will not contain more than 60 or so threads (two bundles that 
large would most likely not fit onto one needle).  
The two objectives that were not fully met are the clamping methods and the seeding 
efficiency. In order to clamp the device, binder clips were used to keep the PDMS pieces 
together. A different clamping method could be used completely, or an entire PDMS mold could 
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be edited. Since the prototypes create rough faces on the PDMS molds, the two pieces do not 
adhere to one another; however, PDMS has the ability to suction to itself if the faces are 
completely smooth. Unfortunately, the seeding efficiency was not maximized as initially hoped 
for. The results obtained a 5% seeding efficiency, which is the minimum for clinical use. The 
project goal was to obtain a seeding efficiency of 12% or greater, but due to time limitations, the 
group was not able to focus on this objective and the minimum efficiency was met. 
Constraints Met 
Without meeting the constraints initially identified, the device would not be labeled a success. 
The product had to be completed by June 28, 2012 under a budget of $468; both of these 
constraints were met. Safety, as discussed earlier, was crucial because without maintaining safety 
to the cell, there would no application for the device and without maintaining safety for both 
client and user, the device would fail and potentially put lives at risk. The device must have the 
ability to be sterilized so that the seeding process can be completed in a biological safety hood 
and PDMS has been proven to be properly sterilized. Along these lines, the product needs to be 
non-hazardous so that the cells can be maintained without worry of contamination or cell death. 
Finally, the device must have a seeding efficiency greater than or equal to 5%. As discussed 
above, the product met the exact minimum and proved to efficiently seed 5% of the hMSCs used. 
Economics 
The device serves to regenerate both heart tissue and blood vessels, in order to resupply the 
tissue with nutrients. If the product is FDA approved and allowed for regular use, it would 
greatly reduce the cost of health care for individuals everywhere. Since heart disease is 
extremely common and myocardial infarctions occur regularly, the use of this device would 
potentially save insurance companies millions of dollars. By regenerating the tissue immediately 
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after an infarction, this product reduces the need for future health care. A heart that maintains its 
ability to pump normally would reduce the incident of congestive heart failure associated with 
ischemic heart disease. The design created by the group can be made inexpensively because the 
plastic mold can be reused as many times as desired (rather than creating multiple molds). Also, 
the new design utilizes all of the same tools as the current single-cell seeding design; therefore, 
the needles, fibrin thread production, media, etc. are all the same and remain inexpensive to 
obtain in a laboratory.   
Environmental Impact 
The use of this product can greatly reduce the need for other surgeries or treatments for the 
individual who suffered the myocardial infarction. Because of this, a severely decreased amount 
of supplies and drugs would be used to treat the patient. PDMS as a solid, which is how it is used 
for this design, can be broken down and converted back to inorganic ingredients, water vapor, 
amorphous silica, and carbon dioxide. Since solid PDMS can be broken down and reused, it does 
not pose a threat to the environment like it would if it were liquid (Dow Corning, 2012). 
Therefore, this product has a great positive impact on the environment by reducing the amount of 
waste created because less material will be used. 
Societal Influence 
This device will improve everyday living for those affected by myocardial infarctions, but it will 
also improve the daily life of the family members and friends of the patients. By helping to 
reduce the cost of treatment and improving the heart function, everyone will benefit from the 
design without worry for continued heart failure due to the initial infarction. 
 
44 
 
Political Ramifications 
Myocardial Infarctions are a prevailing issue all over the world; therefore, this device could be 
used wherever there is access to health care. Since the suture must be surgically implanted, the 
device would only apply for countries with the ability to complete this surgery. However, the 
global market would change and this device would likely be the preference due to its similarity 
to current designs and increase in regenerative abilities. This design could be used with 
Embryonic Stem Cells (ESCs) if they were desired for this use; however, current designs prefer 
to use hMSCs and EPCs. Not only do these two cell types avoid the use of ESCs, and their 
associated ethical issues, but adult cells can also be retrieved from the patient or from other 
mature persons whose cells are more likely to serve the desired person. ESCs are still immature 
cells and although they are highly desired for their totipotency, for the use of regenerative 
medicine it would be more beneficial to use mature cells for faster results.  
Ethical Concern 
This device is used to seed stem cells upon a suture, which leads to many ethical concerns. 
Current ethical issues revolve around the use of embryonic stem cells; however, hMSCs and 
EPCs are naturally occurring in the blood stream and can be harvested from the bone marrow of 
living adults. Therefore, the issue surrounding the use of embryonic stem cells is not applicable 
for the product since the cell donor will be a living human. 
Health and safety issue 
Health and safety issues exist around the surgical procedures currently used to implant the 
suture. Current methods require opening of the chest cavity and fully exposing the heart in order 
to thread the suture through the left ventricle. With this procedure there lies the potential risk of 
45 
 
infection, a very long recovery for the patient and also the understanding that there may be some 
difficulties or encounters with human error. However, these issues are understood for most 
surgeries and until the surgical application is modified, the risks may not decrease. This design 
will likely aid in decreasing health issues related to the heart, but with current research in the use 
of catheters, the suture may be used without the need for opening the chest cavity. As research 
continues to show more efficient use of catheters around the heart, this design may be able to be 
used and to completely avoid all major health/safety issues. 
Manufacturability 
The device can easily be manufactured and mass produced. Since the device consists of items 
that are very often found in a laboratory environment, it would not be difficult for anyone to 
create this product. If one were to mass produce the item, it would also be simple since the only 
part that needs to be created is the PDMS mold and that is rather inexpensive to obtain. The rapid 
prototyped mold, which is used to form the PDMS, could be created by other means, i.e. 
ordering through a plastics company. However, the group chose to rapid prototype the mold 
because the machine is conveniently located on campus and the molds were not difficult to 
obtain within 1-2 days of ordering. 
Sustainability  
The materials used to fabricate this device are extremely small quantities; therefore, the risk of 
depleting these resources is minimal to almost negligible. PDMS is one of many silicones used 
for various applications and it has been proven to be sustainable. Since PDMS breaks down and 
can be reused, it does not present an environmental hazard; also, by using a silicone product, this 
design reduces waste by keeping other resources untouched. The creation of PDMS requires a 
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low curing temperature which reduces energy requirements and the creation process also takes 
only a short amount of time (Dow Corning, 2012). 
Chapter 8: Final Design and Validation 
Myocardial infarction leads to cell death in the heart and our project aims to find a way to deliver 
stem cells to the heart to aid in regeneration of these lost cells. Our device allows for two lines of 
cells to be loaded on to two separate bundles on the same needle, so that when pulled through the 
heart a known ratio of two different stem cells can be delivered to the same area.  
The group chose our final design after evaluating all of our objectives and reassuring that 
our design met the specific aims of our project. We needed to be sure that our design 
successfully loaded two different cell types separately on the same needle and that it was able to 
seed these cell types efficiently. Through brainstorming, interviewing, and analyzing our ideas 
we were able to create a design that fit our objectives and met our revised client statement. 
Additional criteria were taken into consideration, including difficulty to implement, perceived 
gas exchange, and ability to cater to certain design variables. The final design was chosen to be a 
V Design PDMS mold (Figure 11).  
 
Figure 11: Final PDMS Mold 
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Manufacturing and Sterilization 
Before settling on one design, we made rapid prototypes of our top ideas and did several 
preliminary tests to be sure that our design would work. Each prototype was made from 
Acrylonitrile Butadiene Styrene (ABS) plastic by the Rapid Prototype machine in the 
Mechanical Engineering Department at WPI.  These molds were used as a template for the 
PDMS. Once the molds were made, our first test was to confirm that our design was able to 
successfully hold the fibrin suture. Once it was established that this was effective we loaded the 
design with media, clamped it, attached the design to the conical tube rotator and placed it in the 
incubator for a 24 hour period. The last test that was done was an actual cell seeding test.   
Process and Features 
The Final Design has two PDMS molds made from an ABS Rapid Prototype.  The fibrin suture 
was loaded into the Silastic® tubes and laid into the PDMS mold wells.  The second layer of 
PDMS was folded over the tubes and clamped to keep the tubes in a fixed position.  The tubes 
were clamped at the end opposite the needle with clamps that slid over the tubing to hold it. 
These clamps were left open during and closed immediately following cell seeding. The needle 
was situated in the PDMS mold to minimize the amount of PDMS clamped over it; this 
prevented the threads from dehydrating and breaking. After cell loading the design was attached 
to a conical tube rotator by the handles of the binder clips. (See Figure 12 below for an image of 
the final design on the tube rotator) This design was most beneficial since the threads could be 
statically or dynamically loaded.  The design also was made for tubes able to accommodate 4cm 
or 2cm threads. (See Appendix C for CAD file for dimensions)  
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Figure 12: V- Design on Conical Tube Rotator 
The cell seeding process, as outlined in Appendix A, was used to certify that our design 
functioned properly. It was extremely important that our design could be sterilized. We used 
ethylene oxide sterilization. This sterilization method was used as a safeguard for possible 
deterioration by an autoclave machine. The ethylene oxide sterilization was able to sterilize all 
surfaces of the device without heat and without causing damage to the prototype. We then loaded 
our cells into our design and placed it in the incubator. We had to be sure that our design was 
easy to place the suture into, inject fluid into and that it could withstand the temperature of the 
incubator so that this process was successful.  
Chapter 9: Conclusions and Recommendations  
This project improved the existing method of seeding stem cells onto microthreads; however, 
there is plenty of opportunity to develop upon our design and process.  The cell seeding tests 
performed on the sutures demonstrated that two different cell types could be seeded on one 
suture.  Further testing of thread ratios is possible using the final PDMS design.  The media 
retention test showed that the design is capable of holding the media, threads, tubes, and needle. 
The design could also be dynamically rotated using a conical tube rotator.  
At the start of this project many concepts and ideas were proposed on how to seed and 
keep the threads bundles separate until the time of the surgery. These ideas were considered 
outside the scope of this project. One of the these ideas included redesigning the suture needle to 
incorporate an auxiliary component that would allow the surgical preparation team to assemble 
the need with the threads together in the operating room. This would decrease the time and work 
that the manufacturers need to produce the sutures. Another area for improvement exists around 
the containment and sterility of the mold and suture. Efficient containment may be accomplished 
in the future by increasing the area for gas diffusion through the Silastic® tubing or changing the 
material used to allow gas diffusion. The group tested ideas about changing the diameter of the 
tubing and the type of material used for the tubing. If a better material were chosen, this may 
eliminate the need for tubing at all. Static seeding in wells was used in prior research, however 
static seeding has been found to be less effective at seeding certain cell lines onto microthreads. 
Incorporating a design that allows for static and dynamic seeding may facilitate better cell 
seeding. In this project, the PDMS molds were made of ABS plastic from a rapid prototype 
machine. Due to the lack of specificity of the machine, the ABS plastic was not uniformly 
smooth. This resulted in the PDMS molds also not being uniformly flat. The lack of specificity 
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made the edges of the PDMS molds offset when they were clamped together. This misalignment 
may have led to an opening in the final design that allowed air into the tube and media and cells 
to flow out. A similar prototype made of uniformly flat material, may solve this problem.  
The fibrin microthreads represent a large variable in use as a scaffold.  Current 
companies such as VitaThreads® are researching how to most effectively construct the threads to 
optimize different cell line attachment. Dynamic seeding can be done in multiple ways. 
Currently the protocol used in the Gaudette lab utilizes a conical tube rotator to spin the tube 
around a fixed axis. Some dynamic seeding techniques worth researching include a series of 
rotations and stop times. This may allow the cells time to adhere to the microthread scaffold 
rather than being in constant motion. Another technique includes periodically shaking the mold 
with the suture. From a broader perspective, varying cell concentration in the seeding media is a 
possible way to increase seeding efficiency. 
Appendix A:  Protocols 
Cell Thawing 
1. Spray inside surface of hood with 70% Ethanol. Spray all exterior surfaces of containers 
to be brought into hood with 70% Ethanol. Set up all necessary items in hood. 
2. Remove stored cryovials containing cells from Liquid Nitrogen cryotank/Dry Ice. 
3. Thaw cells rapidly by immediately immersing vials into 37°C water bath. Do not 
submerge them completely and watch them closely. Gently agitate for about 2 minutes 
(no longer than 3 minutes). Note: Most cell death occurs between -50° and 0°C when 
thawing.  
4. When fully thawed (all ice crystals melted), remove vials immediately, wipe dry then 
spray outside of vials thoroughly with 70% Ethanol before bringing cells into the hood. 
Transfer thawed cell suspension into 15ml tube containing 5ml pre-warmed media to 
dilute. 
5. Centrifuge cells at 500-600 rpm for 5 minutes to remove any residual DMSO. While cells 
are being spun down, set up new flasks and add appropriate amount of DMEM to each: 
~12-15ml to T75. Temperature equilibrate to 37°C. 
6. Discard supernatant; resuspend cell pellet in minimum volume of fresh pre-warmed 
media. Perform cell counting. Seed cells by transferring the appropriate amount of cell 
suspension into new culture flasks with fresh medium.  Note: amount of suspension 
transferred will depend upon the density at which cells are frozen and desired cell density 
for new seed. 
7. Place cells in incubator and replace with equal volume of fresh medium after 24 hours to 
remove and floating (dead) cells. Observe cells daily growth (confluency reached by ~1 
week) and freedom from contamination. Media to be changed every 3-4 days. 
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8. Clean up hood and spray down surface with 70% Ethanol. 
Cell Counting 
1. Aspirate media and add 5ml DPBS- (for T75 flasks) for 5 minutes. Repeat 3 times. 
2. Aspirate DPBS and add 5ml Trypsin (0.25%) 
3. Place in incubator for 5-10 minutes. 
4. Examine cells under microscope to ensure all cells have detached from plate; if not, 
gently tap plate to detach cells. 
5. Move 5ml trypsin/cell solution to 15ml conical tube and add 5ml media. 
6. Place conical tube in centrifuge at 1000rpm for 5-7 minutes. 
7. Remove supernatant. 
8. Resuspend cells in 1ml media by pipetting. 
9. In 0.65ml microcentrifuge tube, combine 5µl DPBS and 5µl Trypan Blue stain. Vortex. 
10. To this mixture, add 10µl of resuspended cell solution. Mix by pipetting. 
11. Remove 10µl of solution from 0.65ml tube and place on hemocytometer. 
12. Examine hemocytometer under microscope and count total number of cells in the outer 
four quadrants. 
13. Multiple total counted number by 5,000. This value will give you the number of cells per 
1ml media. 
Cell Culture 
Verifying cells are healthy 
1. Take cell culture flask out of the incubator. Take care not to tilt the flask; the media 
should not enter the neck of the flask. 
2. Inspect the media visually: 
a. Color: - should be dark pinkish red. If yellow / yellowish orange – immediate 
action – change media / discard cells. 
b. Transparency: Cells in good health show transparent, clear media. If cloudy  
sign of contamination / aging / dying cell culture. 
3. Microscopic examination: Examine the cell culture flask under an inverted microscope; 
first under low magnification (usually 4x) and then under medium magnification (usually 
10x).  
Things to look for: 
a. Floating cells (dead or unhealthy), cellular debris, bacteria or fungi, other 
unidentifiable debris  signs of unhealthy culture. Immediate action necessary: 
i. If contaminated – suction out all media into waste, spray the inside of the 
flask with alcohol, suction the alcohol, and then discard in biohazard. 
ii. If unhealthy, but not contaminated – change media with fresh, warm 
culture media. Examine again after 24 hours and feed with fresh media 
again. 
b. If cells are nicely spread out (adhered), look for vacuoles within the cells. 
Presence of too many vacuoles is an indication that the media needs to be 
changed. 
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c. Confluence of culture  Look, at least, at 5 locations within the flask, usually 
four corners and the center. Calculate confluence and note it down. For 80 – 100 
% confluence – passage the cells. For cultures older than 14 days – passage the 
cells, irrespective of confluence. For the rest, replace old media with fresh media 
(which is referred to as “feeding the cells.”) 
Preparing the Hood 
4. Take cell culture cart from lab bench area to cell culture room, along with 1000 µL 
micropipette / pipette aid (depending upon flask size), corresponding sterile pipette tips 
and other items as necessary. 
5. Put gloves on, spray hands with alcohol. (do this every time something unclean/not sterile 
is touched) 
6. Spray the inside of the laminar flow hood (working surface and bottom third of the side 
walls) and wipe down. Make sure to clean the vacuum line also, by spraying both the 
outside and inside of the tube with the vacuum turned on. 
7. Spray and wipe all objects that you intend to take inside the laminar flow hood. Be 
careful not to spray the cap of the flasks the cells are in. 
8. Attach the Pasteur pipette on the vacuum tube and place it in a manner that the tip doesn’t 
touch any object while you work in the hood. Set up all other items in the hood. 
9. Bring warm media from the water bath and the cells from the incubator. WIPE DOWN 
MEDIA AND CELL CULTURE FLASKS THOROUGHLY WITH ALCOHOL, as the 
water bath and incubator are common sources of contamination. 
Feeding 
10. Unscrew the flask cap and place it in a way that its inner side doesn’t touch anything 
while you’re working on the flask. Tilt the flask so as to accumulate the media in one 
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corner of the closed end of the flask (opposite the open end through which you insert the 
Pasteur pipette).  
11. Insert the Pasteur pipette slowly taking care not to touch any inner walls of the flask. 
Suction the media out from the cell culture flask taking care not to touch the bottom 
surface, where the cells are attached. 
12. Add 4mL (or required volume) of fresh, sterile, warmed media with a 
micropipette/pipette. Take care not to touch any part of the flask (especially inner surface 
of the neck) with the pipette tip while dispensing media. If the tip touches any surface 
accidentally, discard the tip and use a fresh one. It’s important not to contaminate the 
stock solution of media, therefore use only a fresh, sterile tip to aspirate media from its 
storage bottle. 
13. Cap the cell culture flask immediately after media is added screw the cap on tight. Return 
the cell culture flask to the incubator. (As a general rule, try keeping the cells out of the 
incubator for as short a duration as possible: mammalian cells like to be in a 37oC-
environment – that of the incubator). 
Clean-up 
14. Cap all bottles (media, sterile PBS, other) tightly, remove all objects from the laminar 
flow hood. Spray the inside of the laminar flow hood with alcohol, and wipe down. Be 
sure to clean the vacuum line as well.  
15. Switch off the light of the laminar flow hood. (DO NOT turn on the UV light unless 
explicitly instructed to do so). 
16. Return all items to their designated storage places.  
17. Update Cell Culture inventory / inform your mentor. 
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Cell Passage 
1. Aspirate media and add 5ml DPBS- (for T75 flasks) for 5 minutes. Repeat 3 times. 
2. Aspirate DPBS and add 5ml Trypsin (0.25%) 
3. Place in incubator for 5-10 minutes. 
4. Examine cells under microscope to ensure all cells have detached from plate; if not, 
gently tap plate to detach cells. 
5. Move 5ml trypsin/cell solution to 15ml conical tube and add 5ml media. 
6. Place conical tube in centrifuge at 1000rpm for 5-7 minutes. 
7. Remove supernatant. 
8. Resuspend cells in 20ml media. 
9. Pipette 10ml cell solution into new T75 flask. Repeat this step. 
Thread Production 
1. Remove three 200µl Thrombin and three 1mL Fibrinogen aliquots from the -12°C 
freezer. 
2. Thaw the aliquots by fixing them in the foam floatation pad and then placing the pad in a 
cup of cold tap water for ~2min or until thawed. 
3. After the aliquots have thawed, use a 1000µl pipette to add 800µl of CaCl2 to each 200µl 
Thrombin aliquot. Mix the solution by closing the cap and gently rotating the tube in 
your hand, DO NOT SHAKE. 
4. Label the syringes “T” and “F” for Thrombin and Fibrinogen, respectively. 
5. Attach a needle to the 3mL syringe labeled “T” and draw up 3 Thrombin-CaCl2 solutions 
preparations. 
6. Attach a needle to the 3mL syringe labeled “F” and draw up the 3 Fibrinogen 
preparations. 
Note: While loading the solutions into the syringes insure that all air bubbles 
are removed before proceeding to the next step. 
Syringe Pump 
1. Load the syringes containing the Thrombin and Fibrinogen into the syringe pump.  
a. Lift black knob and slide the ends of the syringes under black bar, splitting the 
two syringes with the knob. Make sure syringe flanges are inserted in to clamp. 
Release black knob. 
b. Tighten syringe clamp using the silver nuts. 
c. Use the small white syringe connector to keep the syringe plungers together. 
Attach to the end of the plunger.  
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Figure A1: Syringe Set-up 
2. Power up the syringe pump by using the power switch located on its back left. 
3. On the front of the syringe pump, press the button labeled ”diameter” twice, and then use 
the arrow buttons to the left to set the value at 7.62mm. 
4. Press the button labeled “rate” and use the arrow buttons to the left to set the value at 
0.1mL/min. 
5. On top of the fibrin thread extruder, attach the tubes labeled “T” and “F” using integrated 
luer lock hubs to the tips of the syringes containing Thrombin and Fibrinogen, 
respectively. 
 
Connector goes here This part goes in the clamp 
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Extruder 
1. Using the username “BIO12\gaudettelab” and the password “Glenn2012”, log into the 
computer located to the left of the fibrin microthread extruder. 
2. Open the program titled “NI Motion Assistant” located on the desktop. 
3. At the top of the program click on “Add Step\Reference Move”. Then at the bottom of 
the program under the tab labeled “Configure” click on the 3-D button. Next, click on the 
tab at the top of the program labeled “Step Status”. 
4. From this screen, use the X, Y, and Z coordinate arrow buttons to toggle the extruder 
head until it is positioned above a clear space on the floor of the machine. 
5. Place an empty 50mL beaker in the clear space underneath the extruder head. 
6. Attach a 3mL syringe filled with DI water to the Thrombin “T” tubing line and inject the 
water through the line into the beaker, thus clearing the line of any debris. Repeat 2 
times, or until tubing is completely clear of debris. 
7. Repeat step 6 for the Fibrinogen “F” tubing line. 
8. Attach a 60mL syringe filled with air to the “T” line and blow air through the tubing in 
order to clear it of all residual DI water. Repeat twice or until all water is removed. 
9. Repeat step 8 for the “F” tubing line. 
10. Pour ~300mL of 10mM HEPES solution into each bath. 
11. Open the Labview Virtual Instrument (VI) labeled “J6 Extruder VI”. 
C:\users\user\desktop\j6 extruder vi 
12. On the front panel of the VI, set the number of threads to 15, the extrusion head velocity 
to 100, and the speed between baths to 200.  
62 
 
13. Activate the desired baths within the VI path planning by clicking on the appropriate red 
dots, thus making them green. The front panel should similar to Figure 2.  
 
Figure A2: Fibrin Microthread Extruder VI 
14. Home the extrusion tip by clicking the arrow button  located at the top left of the front 
panel. The tip will be homed when it is positioned above the top right corner of Bath 1. 
At that time stop the tip by clicking the pause button . 
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Figure A3: Home Position 
15. While the VI is paused at home, start the syringe pump by pressing the start button. 
16. Once the Thrombin and Fibrinogen solution begins to flow out of the extruder tip, click 
the red pause button  to reactivate the VI. Allow the VI to extrude microthreads until 
the Thrombin and Fibrinogen syringes are fully depleted. 
Note: During extrusion, if a glob of fibrin adheres to the extruder tip, then 
swiftly use tweezers to remove it. Failure to do so will result in irregular 
shaped fibrin threads.  
17. During the extrusion, fill two 3mL syringes with DI water. 
18. After the extrusion is complete, click the pause button   to halt the process. 
Extruder 
i
Bath #1 
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19. Immediately replace the syringes on the syringe pump with the two 3mL syringes filled 
with DI water, reset the syringe pump at the same diameter and rate as before, and press 
the red pause button  to reactivate the VI. 
Note: This step must be preformed swiftly (under 30 sec) in order to avoid 
the formation of a blockage in the microtubing of the extruder tip. 
20. Once threads are no longer observed to be forming in the baths, Press the start/ stop 
button on the syringe pump, and the stop button  on the VI to end the process. 
21. In order to avoid the formation of a blockage in the “F” and “T” tubing lines repeat steps 
4-9. 
22. Allow fibers to stand for a minimum of 15 minutes in bath to cure. 
Following curing, fibers should be further processed by stretching and drying. 
Thread Stretching 
1. After curing, remove the baths containing the Fibrin threads from the extruder and place 
them on the lab bench. 
2. Using two sets of tweezers, grasp both ends of the first thread and gently peel it off of the 
bottom of the well while lifting it out of the HEPES solution. 
3. Stretch the thread by dragging it back and forth through the HEPES solution until it is 
approximately twice its original length. 
4. Gently hang the thread across the top of the drying rack by touching one end, and the 
midpoint of the thread to the sides.  
5. Repeat steps 2-4 for each thread in the baths. 
6. Allow the threads to dry on the racks under ambient conditions for 30 minutes. 
Thread Bundling 
1. Adhere a (~1x1cm) piece of laboratory tap to the top-center of an 8.5x11inch plastic 
sheet. 
2. Remove the dried threads from the racks by grasping the ends with tweezers. 
3. Slightly lift up an edge of the tape and press it down on one end of a thread.  
Note: The thread should adhere to the tape and not the plastic, allowing for 
the tape to be lifted up again. 
4. Repeat step 3 until 12 threads are adhered to the piece of tape, making sure that they are 
positioned together as close as possible. 
 
Figure A4: Taped Threads 
Tape
12 Fibrin Threads
8.5x11 inch Plastic Sheet
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5. After 12 threads are attached to the tape, fold it onto itself and clamp it to the top of the 
bundling rack so that the threads are dangling above an empty beaker. 
6. Using a pipette carefully drop DI water down the length of the threads, insuring that they 
become fully hydrated and adhere together. 
7. Once fully hydrated, grasp the bottom end of the thread bundle with your thumb and 
forefinger and slowly perform ~20 twists in the same direction.  
Note: While twisting, insure that the entire length of the thread bundle is 
twisted, and that it does not become dry. If necessary, twist from the center 
of the bundle, and rehydrate. 
8. Ensure the thread bundle is straight and clamp the loose end to the bottom of the bundling 
rack. 
9. Allow the thread bundle to dry under minimal tension for 30 minutes.  
Note: After securing both ends of the bundle to the rack, its length should be a minimum of 
16cm. 
Needle Attachment 
1. Fill a large petri dish with DI water. 
2. Use tweezers to remove the thread bundles from the bundling rack and place them on 
the plastic sheet. 
3. Sever ½ cm from each end of the thread bundle with iris scissors. 
4. Using a ruler and iris scissors, divide the 16cm thread bundle into 8cm sections. 
5. Thread the 3/8ths circle tapered needle with the one 8cm section and then place it on the 
bottom of the petri dish filled with DI water. 
6. Allow the threaded needle to soak in the DI water for ~2min.  
7. Remove the threaded needle from the bath and place on the plastic sheet. 
8. Position the bundle so that it is straight off to the side of the needle. 
9. Using tweezers, lift the needle off the plastic sheet and grasp the two loose ends of the 
thread bundle with your thumb and forefinger. 
10. Gently squeeze and twist the ends ~10 times to form a uniform suture. 
a. As necessary, moisten thread bundle using a pipette and DI water. 
11. Place the suture on the plastic sheet and let dry under ambient conditions for ~5min.  
Repeat for the other bundle on this same needle. 
12. Using forceps lift up a dried suture and carefully slide each bundle into a separate 6cm 
tube.  
13. Place both tubes into the intended tube wells in the PDMS mold.  
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Figure A5: Final Design PDMS with suture in tubes 
14. Place other PDMS mold on top and clamp tight, making sure to fit the key into the lock. 
 
Thread Seeding 
1. Place entire design into Autoclave bags and EtO sterilize all required utensils overnight. 
2. Remove utensils from autoclave bag in the hood to ensure sterilization.  
3. Hydrate threads with DPBS for 15 minutes. 
4. Count cells (See Protocol) and resuspend each solution so that the concentration is 
approximately 100,000cell/1ml. Keep note of exact concentration. 
5. Use 1 ml syringe with 27 G ½ injection needle attached and fill to the .2ml line for each 
solution.  
6. One at a time, inject 100µl of solution into each tube and clamp over the overhanging 
tubing. 
a. Note: Insure that the needle does no puncture the tubing. 
7. Repeat for each suture. 
8. Attach design to the conical tube rotator and place in incubator at 37°C with 5% CO2 
concentration for 24 hours. 
Quantum Dot Loading 
1. When cell solution appears to be 80-100% confluent, follow through with protocol 
2. Mix 10ml media with 10µl Qdot solution, obtained from the refrigerator. This ratio 
remains the same, i.e. for 100ml media, 100µl Qdot solution would be used. 
3. Vortex mixture. 
4. Aspirate media for the confluent culture. 
5. Add mixture of Qdot solution and media. 
6. 24 hours after addition of mixture, aspirate mixture and add 10ml media. 
Hoechst Staining 
1. Aspirate media from cells, wash cells twice with PBS. 
2. Fix cells in a solution of 1-3% formaldehyde ("formalin") in PBS at RT for 10-20 
minutes (typically 1.5% formaldehyde, which is a 25 fold dilution of commercially 
available 37% formaldehyde; do not use cloudy formaldehyde and avoid the precipitate 
that forms at the bottom of the bottle). Use enough solution to cover dish thoroughly (1 
ml/ 35 mm dish). 
3. Aspirate fix solution, add cold (–20°C) 100% methanol; leave at room temperature for 20 
minutes (permeabilization step).  
4. Aspirate methanol, rinse thoroughly three times with PBS. 
5. Add a 1:10,000 dilution of Hoechst stock in PBS (dilute fresh each time; final 
concentration is 0.12 µg/ml). Incubate 15 minutes at RT. 
6. Rinse about five times with PBS. 
7. Visualize. Must have a light source providing light at 340-380 nm. Emission maximum is 
at 465 nm. We have used a Leitz or Zeiss microscope equipped with a mercury bulb and 
a Leitz "A" filter, or a Zeiss "01" filter. Hoechst stain will bleach!! Protect stained dishes 
from light except when analyzing. Dishes can be restained, however. 
PDMS Creation 
1. Weigh 10 parts Sylgard® silicone elastomer base and 1 part Sylgard® silicone elastomer 
curing agent.  Note: DO NOT MIX THE STOCK SOLUTIONS!!!  Use separate 
weighing materials for each reagent. 
2. Thoroughly mix the elastomer base and curing agent. 
3. Pour the well mixed solution into your mold. 
4. Degass the PDMS by putting it into a vacuum chamber for at least 1 hour (larger/thicker 
volumes of PDMS may require more time). 
5. After degassing, visually inspect the PDMS to ensure that there are no more bubbles.  If 
there are, repeat steps 4 and 5. 
6. Cure the PDMS by placing the mold into an oven set for 60 °C for at least 4 hour (larger 
samples may require more time). 
 
One important thing to keep in mind is that the uncured reagents are very tacky and can make a 
big mess of anything they contact (the degassing chamber, the scale used to weigh reagents).  
Students should wear gloves when handling PDMS, be careful not to spill, and make sure they 
clean up the space and equipment they use when preparing PDMS.   We keep “Goo Gone” in the 
lab for this reason. 
Appendix B  
Legend: 
        Quantum Dot Stain 
        Hoechst Stain 
Quantum Dot Cell Images 
 
Quantum Dot Overlay 10x Image 
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Quantum Dot Overlay 10x Image
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Overlay of A and B 
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Suture Images 
 
 
Suture on slide before removing needle 
Suture during PBS wash 
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Bundle Images 
 
 
Hoechst Stain Image 10x 
Hoechst Stain Image 10x 
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Non-QD Cell Bundle in QD Image 
Hoechst Stain Image 10x C 
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QD Image 10x 
Overlay of C and D 10x 
D 
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Hoechst Stain Image 10x 
QD Image 10x 
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Overlay of E and F 10x 
Hoechst Stain Image 10x 
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Needle Drawings 
Magnetic Needle Design 
 
Drill End Needle Design 
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Clip-In Needle Design  
Appendix C 
Parallel Tube Design CAD 
 
 
Top 
Bottom 
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Rotating Disc Design CAD 
 
 
2 of these pieces 
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Suture Well Design CAD 
 
 
Base 
Removable rod 
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First V Design without walls CAD 
 
Final Design: V Design CAD 
 
 
Dimensions are in centimeters 
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Pairwise Comparison Charts- Group 
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Pairwise Comparison Charts- Professor Gaudette 
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Pairwise Comparison Charts- Mark Kowaleski 
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Morphological Chart 
 
Due to inefficient seeding of cells, the suture well design and the parallel tube design were not 
chosen as possible products. 
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Appendix E 
Account Number: GRG-1301 
Total Funds for project: $468 
Below is a list of materials that will be used and an estimated cost of each. 
 Quantum Dots 
 T75 culture container 
 Cell Culture Materials 
o Dulbecco’s Modified Eagle Medium (DMEM) 
o Fetal Bovine Serum (FBS) stock solution 
o Penicillin-streptomycin 
 Acrylonitrile Butadiene Styrene (ABS) plastic prototype molds 
 Clamps 
o Slide-able 
o Pressure 
 Ethylene oxide gas ampules 
 Thrombin  
 Fibrinogen 
 ½ inch semi circle needles 
 Silastic® tubing 
 27G½ syringe needles 
 1ml syringes 
 3ml syringes 
 Serological pipette and 10ml serological pipette tips 
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 10μl pipette and sterile tips 
 100μl pipette and sterile tips 
 Lonza Human Mesenchymal Stem Cells 
 Microscopy slides 
 Hoechst stain 
 Phosphate-Buffered Saline (PBS) 
 Dulbecco’s Phosphate-Buffered Saline (DPBS) 
 
